Project Grant R43AR073036

Grant Award Summary Gavia Bio, LLC received a $314,363 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on September 5, 2025, with a completion date of August 31, 2026. The award funds Phase I preclinical development of DGL13K, a patented antimicrobial peptide designed as a novel topical treatment for drug-resistant burn wound infections. The project addresses a critical clinical...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $474,363.00 to Rowan University to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The goal is to create new peptide molecules that mimic daptomycin's key mechanisms of action, such as calcium binding and lipid membrane disruption, while improving resistance to...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,995 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Xiretsa Inc., a minority-owned small business located in Santa Barbara, CA. The grant will fund the development of a novel class of antimicrobial compounds called Anti-Infective Conjugated Electrolytes (ACEs) that target the bacterial cell membrane to address the growing threat of antimicrobial resistance. The project...

The National Science Foundation (NSF) awarded a $451,276 Project Grant to the University of Texas at Arlington (UTA) under the Mathematical and Physical Sciences (MPS) program (CFDA 47.049) for the project "Design of pH-Responsive Peptide Assembly for Acid-Activatable Antimicrobial Therapy." The project aims to develop self-assembling antimicrobial nanofibers that are activated in acidic environments, such as those found in infections, to effectively kill antibiotic-resistant...

Grant Award Summary Halomine Inc., doing business as Avantguard, received a $299,435 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded August 1, 2025, with completion scheduled for July 31, 2026. The grant supports the development and optimization of a novel, bio-inspired stabilized chloramine formulation designed to treat cutaneous fungal infections, particularly tinea (ringworm),...

Federal Project Grant Award Summary Microbiotix, Inc. received a $299,946 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 22, 2025, with completion targeted for August 31, 2027. The award supports the development of novel benzyl-piperidine (BP) antifungal agents to treat intractable mucormycosis infections caused by the Mucorales fungal order, a World Health...

This Project Grant award from the National Science Foundation (CFDA 47.074 - Biological Sciences) provides $104,236.00 to support a team of undergraduate students from the University of Virginia in developing a low-cost, non-invasive, effective topical treatment for Staphylococcus-based cellulitis. The project aims to produce skin-penetrating antimicrobial peptides specific to Staphylococcus with the potential for scalable production. Through this effort, the students will receive hands-on...

Grant Award Summary Temple University received a $158,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2027. The award supports an exploratory study to develop and validate a novel pH-responsive, ionizable hybrid nanocarrier system designed to enhance therapeutic drug delivery to bacterial biofilms. The research focuses on creating a...

Federal Grant Award Summary Siolta Therapeutics Inc. received a Project Grant of $529,498 from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded on August 5, 2025, with a completion date of July 31, 2028. The company is developing STMC-105, a multispecies live biotherapeutic product (LBP) designed to prevent recurrent bacterial vaginosis (RBV) in women of reproductive age. The therapeutic product combines...

Federal Grant Award Summary Florida International University received a $184,375 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period August 1, 2025 through July 31, 2027. The project focuses on the optimization and development of a novel antimicrobial peptide designated A4-X7 for aerosolized pulmonary delivery to treat multidrug-resistant (MDR) bacterial respiratory infections...